Fall Clinical 2025 News: Castle’s DecisionDx-Melanoma Stratifies Risk Across Histological Subtypes
Castle Biosciences, Inc.’s DecisionDx-Melanoma test stratifies melanoma-specific survival across histological subtypes in patients with cutaneous melanoma, according to a study presented at the 2025 Fall Clinical Dermatology Conference in 2025, in Las Vegas, NV.